Search

Your search keyword '"Jolliet, Pascale"' showing total 568 results
Start Over Author "Jolliet, Pascale"
568 results on '"Jolliet, Pascale"'

152. An Update on Zolpidem Abuse and Dependence

Author

Victorri-Vigneau, Caroline, primary, Gérardin, Marie, additional, Rousselet, Morgane, additional, Guerlais, Marylène, additional, Grall-Bronnec, Marie, additional, and Jolliet, Pascale, additional

Published
2014
Full Text
View/download PDF

154. Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis

Author

Mahe,Julien, Meurette,Aurélie, Moreau,Anne, Vercel,Caroline, Jolliet,Pascale, Mahe,Julien, Meurette,Aurélie, Moreau,Anne, Vercel,Caroline, and Jolliet,Pascale

Abstract

Julien Mahe,1 Aurélie Meurette,2 Anne Moreau,3 Caroline Vercel,2 Pascale Jolliet1,4 1Clinical Pharmacology Department, Institute of Biology, University Hospital, Nantes, France; 2Clinical Nephrology and Immunology Department, University Hospital, Nantes, France; 3Laboratory of Pathology, University Hospital, Nantes, France; 4EA 4275 Biostatistics, Pharmacoepidemiology and Subjective Measures in Health Sciences, University of Nantes, Nantes, France Abstract: Interferon beta-1a is available as an immunomodulating agent for relapsing forms of multiple sclerosis. Common side effects include flu-like symptoms, asthenia, anorexia, and administration site reaction. Kidney disorders are rarely reported. In this study we describe the case of a woman who has been undergoing treatment with interferon beta-1a for multiple sclerosis for 5 years. She developed a hemolytic-uremic syndrome with intravascular hemolysis in a context of severe hypertension. A kidney biopsy showed a thrombotic microangiopathy. This observation highlights an uncommon side effect of long-term interferon beta-1a therapy. Pathophysiological mechanisms leading to this complication might be explained by the antiangiogenic activity of interferon. Keywords: thrombotic microangiopathy, interferon beta, hemolytic-uremic syndrome, antiangiogenic activity

Published
2013

155. ZORRO: When the mask falls off—Comment.

Author

Istvan, Marion, Laforgue, Edouard‐Jules, Guerlais, Marylène, Jolliet, Pascale, and Victorri‐Vigneau, Caroline

Subjects
BENZODIAZEPINES, MEDICAL personnel, PSYCHIATRIC drugs, CENTRAL nervous system stimulants, DRUGS of abuse, DRUG abuse, SUBSTANCE abuse
Abstract

Keywords: benzodiazepines; drug abuse; drug safety; drug utilisation; psychotropic drugs EN benzodiazepines drug abuse drug safety drug utilisation psychotropic drugs 2450 2451 2 04/13/22 20220501 NES 220501 We would like to thank the authors of the reply for their interest in our study1 and for providing some very interesting points for discussion.2 Our addictovigilance centre has been responsible for the national surveillance of zolpidem abuse or dependence in France for more than 20 years. Benzodiazepines, drug abuse, drug safety, drug utilisation, psychotropic drugs Prevalence of cocaine use and cocaine use disorder among adult patients with attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. [Extracted from the article]

Published
2022
Full Text
View/download PDF

156. Molecular Properties and Pharmacokinetic Behavior of Cetirizine, a Zwitterionic H 1 -Receptor Antagonist

Author

Morin, Christophe, Zini, Roland, Tillement, Jean-Paul, Bertelli, Aldo, Bertelli, Alberto A.E, Cormier, C, Tillement, J.-P, Lagrue, Gilbert, Simon, Nicolas, Tillement, J.P, Cormier, Anne, Charbonnier, Peggy, Louet, Hervé Le, Jolliet, Pascale, Urien, Saïk, Thiault, Laetitia, Brée, Françoise, Sapena, Rosa, Morin, Didier, Lehri-Boufala, Sonia, Ouidja, Mohand-Ouidir, Barbier-Chassefière, Véronique, Hénault, Emilie, Raisman-Vozari, Rita, Garrigue-Antar, Laure, Papy-Garcia, Dulce, Arendt, Thomas, Zhang, Ganlin, Zhu, Xiaoxin, Bao Huynh, Minh, Ouidir Ouidja, Mohand, Sepulveda-Diaz, Julia Elisa, Li, Ping, Huynh, Minh Bao, Carpentier, Gilles, Garcia-Filipe, Stephanie, Talhas-Perret, Sofia, van Kuppevelt, Toin, Martelly, Isabelle, Albanese, Patricia, Yue, X-L, Lehri, S, Barbier-Chassefière, C, Petit, P., Huang, Q-F, Barritault, Denis, Caruelle, C, Petit, Emmanuel, Kerros, Marie-Emmanuelle, Ikeda, Yasunori, Brugère-Picoux, Jeanne, Deslys, Jean-Philippe, Adjou, Karim, Barbosa, Isabelle, Garcia, Stephanie, Duchesnay, Arlette, Oudghir, Mustapha, Jenniskens, Guido, Miao, Hua-Quan, Guimond, Scott, Cebrian, José, Caruelle, Jean-Pierre, Turnbull, Jeremy, Laurencé, Céline, Rivard, Michael, Martens, Thierry, Buisson, Didier, Bourcier, Sophie, Sablier, Michel, Oturan, Mehmet, Roumegous, A., Barbier-Chassefiere, V., Caredda, S., Courty, J., Pagliara, Alessandra, Testa, Bernard, Carrupt, Pierre-Alain, Urien, Saik, Rihoux, Jean-Pierre, Université Paris-Est Créteil Val-de-Marne - Faculté de médecine (UPEC Médecine), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Mondor de recherche biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Laboratoire de Pharmacologie, Centre de Tabacologie, Hôpital Albert Chenevier, Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Laboratoire de Chimie et Biologie des Métaux (LCBM - UMR 5249), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Centre hospitalier universitaire de Nantes (CHU Nantes), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Croissance cellulaire, réparation et régénération tissulaires (CRRET), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Centre National de la Recherche Scientifique (CNRS), OTR3 Sarl, OTR3, Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Recherches en cancérologie, Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Neuroanatomy University of Leipzig, Leipzig University, College of Information and Electrical Engineering [Beijing] (CIEE), China Agricultural University (CAU), Department of Biochemistry, University of Nijmegen, Laboratoire Astrophysique de Toulouse-Tarbes (LATT), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire Midi-Pyrénées (OMP), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Institut de Recherche pour le Développement (IRD)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Centre National de la Recherche Scientifique (CNRS), Biologie des Plantes et Innovation - UR UPJV 3900 (BIOPI), Université de Picardie Jules Verne (UPJV)-Transfrontalière BioEcoAgro - UMR 1158 (BioEcoAgro), Université d'Artois (UA)-Université de Liège-Université de Picardie Jules Verne (UPJV)-Université du Littoral Côte d'Opale (ULCO)-Université de Lille-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-JUNIA (JUNIA), Université catholique de Lille (UCL)-Université catholique de Lille (UCL)-Université d'Artois (UA)-Université de Liège-Université du Littoral Côte d'Opale (ULCO)-Université de Lille-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-JUNIA (JUNIA), Université catholique de Lille (UCL)-Université catholique de Lille (UCL), Laboratoire d'océanographie de Villefranche (LOV), Observatoire océanologique de Villefranche-sur-mer (OOVM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Groupe d'Innovation Diagnostique et Thérapeutique sur les Infections à Prions, Département de Recherche Médicale-DSV/DRM-Commissariat à l'Energie Atomique (CEA-Fontenay aux Roses), Institut de Biologie François JACOB (JACOB), Cancer and Vascular Biology Center, The Bruce Rappaport Faculty of Medicine, School of Biological Sciences, University of Liverpool, Institut de Chimie et des Matériaux Paris-Est (ICMPE), Institut de Chimie du CNRS (INC)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Centre National de la Recherche Scientifique (CNRS), Institut de Chimie Moléculaire Organique (ICMO), Université Paris-Sud - Paris 11 (UP11), Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques (LCBPT - UMR 8601), Université Paris Descartes - Paris 5 (UPD5)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Physico-chimie des Polymères et des Interfaces (LPPI), Fédération INSTITUT DES MATÉRIAUX DE CERGY-PONTOISE (I-MAT), Université de Cergy Pontoise (UCP), Université Paris-Seine-Université Paris-Seine-Université de Cergy Pontoise (UCP), Université Paris-Seine-Université Paris-Seine, Laboratoire des mécanismes réactionnels (DCMR), École polytechnique (X)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Université de Lausanne = University of Lausanne (UNIL), Laboratoire de chimie analytique pharmaceutique (LCAP), Université de Genève = University of Geneva (UNIGE)-Ecole de Pharmacie Genève Lausanne (EPGL), Unité de Soins Intensifs [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Université Fédérale Toulouse Midi-Pyrénées-Météo-France -Institut de Recherche pour le Développement (IRD)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Centre National de la Recherche Scientifique (CNRS), Université de Picardie Jules Verne (UPJV), Université de Lausanne (UNIL), University of Geneva [Switzerland]-Ecole de Pharmacie Genève Lausanne (EPGL), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire Midi-Pyrénées (OMP), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Observatoire Midi-Pyrénées (OMP), Météo France-Centre National d'Études Spatiales [Toulouse] (CNES)-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Météo France-Centre National d'Études Spatiales [Toulouse] (CNES)-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Models, Molecular, Octanols, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Blood Proteins/metabolism, Molecular Conformation, [SDV.BC.BC]Life Sciences [q-bio]/Cellular Biology/Subcellular Processes [q-bio.SC], 01 natural sciences, chemistry.chemical_compound, Betaine, Drug Discovery, [SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB], Cetirizine/*chemistry/metabolism/*pharmacokinetics, ComputingMilieux_MISCELLANEOUS, Histamine H1 Antagonists/*chemistry/metabolism/*pharmacokinetics, ddc:615, 0303 health sciences, biology, [SDV.BBM.BS]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Structural Biology [q-bio.BM], Brain, Blood Proteins, Hydrogen-Ion Concentration, Cetirizine, Dissociation constant, Hydroxyzine, Lipophilicity, Histamine H1 Antagonists, Molecular Medicine, medicine.drug, Stereochemistry, Serum albumin, Hydroxyzine/chemistry, 03 medical and health sciences, Isomerism, Pharmacokinetics, [SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication, Alkanes, medicine, Animals, Brain/metabolism, Humans, [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM], 030304 developmental biology, 010401 analytical chemistry, Antagonist, Water, Biological Transport, Hydrogen Bonding, Rats, 0104 chemical sciences, chemistry, Zwitterion, biology.protein, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology
Abstract

The ionization and lipophilicity behavior of the antihistamine (H1-receptor antagonist) cetirizine was investigated, showing the drug to exist almost exclusively as a zwitterion in the pH region 3.5-7.5. In this pH range, its octanol/water lipophilicity is constant and low compared to cationic antihistamines (log D = log PZ = 1.5), whereas its H-bonding capacity is relatively large (delta log PZ > or = 3.1). Conformational, electronic, and lipophilicity potential calculations revealed that zwitterionic cetirizine experiences partial intramolecular charge neutralization in folded conformers of lower polarity. Pharmacokinetic investigations have shown the drug to be highly bound to blood proteins, mainly serum albumin, and to have a low brain uptake, explaining its lack of sedative effects. As such, cetirizine does not differ from "second-generation" antihistamines. In contrast, its very low apparent volume of distribution in humans (0.4 L kg-1, smaller than that of exchangeable water) implies a low affinity for lean tissues such as the myocardium and is compatible with the absence of cardiotoxicity of the drug. The zwitterionic nature and modest lipophilicity of cetirizine may account for this pharmacokinetic behavior. The suggestion is offered that cetirizine and analogous zwitterions, whose physicochemical, pharmacokinetic, and pharmacodynamic properties differ from those of "first-" and "second-generation" drugs in this class, could be considered as "third-generation" antihistamines.

Published
1998
Full Text
View/download PDF

160. Multicentre study for validation of the French addictovigilance network reports assessment tool.

Author

Victorri‐Vigneau, Caroline, Hardouin, Jean Benoit, Rousselet, Morgane, Gerardin, Marie, Guerlais, Marylène, Guillou, Morgane, Bronnec, Marie, Sébille, Véronique, and Jolliet, Pascale

Subjects
DRUG monitoring, DRUG analysis, MEDICINAL plants, SUBSTANCE-induced disorders, DRUG addiction
Abstract

Aims The French health authority (ANSM) is responsible for monitoring medicinal and other drug dependencies. To support these activities, the ANSM manages a network of 13 drug dependence evaluation and information centres (Centres d'Evaluation et d'Information sur la Pharmacodépendance - Addictovigilance - CEIP-A) throughout France. In 2006, the Nantes CEIP-A created a new tool called the EGAP (Echelle de GrAvité de la Pharmacodépendance- drug dependence severity scale) based on DSM IV criteria. This tool allows the creation of a substance use profile that enables the drug dependence severity to be homogeneously quantified by assigning a score to each substance indicated in the reports from health professionals. This article describes the validation and psychometric properties of the drug dependence severity score obtained from the scale ( NCT01052675). Method The validity of the EGAP construct, the concurrent validity and the discriminative ability of the EGAP score, the consistency of answers to EGAP items, the internal consistency and inter rater reliability of the EGAP score were assessed using statistical methods that are generally used for psychometric tests. Results The total EGAP score was a reliable and precise measure for evaluating drug dependence (Cronbach alpha = 0.84; ASI correlation = 0.70; global ICC = 0.92). In addition to its good psychometric properties, the EGAP is a simple and efficient tool that can be easily specified on the official ANSM notification form. Conclusion The good psychometric properties of the total EGAP score justify its use for evaluating the severity of drug dependence. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

162. Parachuting: a dangerous trend in recreational psychoactive substance delivery

Author

Boels, David, Grall-Bronnec, Marie, Guerlais, Marylène, Le Roux, Gael, Spiers, Andrew, Gerardin, Marie, Lomenech, Hélène, Bretaudeau-Deguigne, Marie, Daveluy, Amélie, Turcant, Alain, Jolliet, Pascale, and Victorri-Vigneau, Caroline

Abstract

ABSTRACTIntroduction: Medicine diversion for recreational use is a constant concern for health authorities. Parachuting, also refered to as bombing, is used in order to increase the expected effect, to accelerate time-to-onset and to create mixtures of medicines and substances.Aeras covered: Firstly, we analyzed all available scientific literature (PRISMA) and internet forums without any limiting timeframe. Secondly, we collected cases of parachuting reported in the west of France by the addictovigilance and poison control centres. Our study confirms the reality of this emerging issue associated with a higher medical risk (60% of intoxication cases were moderate-to-severe in our study). The substances involved in parachuting were primarily stimulants, with a majority of MDMA, although the use of diverted medication and psychotropes is also of concern.Expert opinion: Parachuting is a dangerous way of using substances and of diverting medicines. This type of administration gives users a certain pharmacokinetic latitude to ‘play’ with respect to substances and medicines. Medicine abuse deterrent formulations do not seem to be sufficient in preventing diversions. This dangerous method of using substances and of diverting medicines should drive pharmaceutical companies to innovate in the interest of public health and safety.

Published
2017
Full Text
View/download PDF

164. Role of the Post-Marketing Authorisation Studies in Drug Risk Surveillance: Specifications and Methodologies

Author

Tubach, Florence, primary, Lamarque-Garnier, Véronique, additional, Castot, Anne, additional, Auclert, Laurent, additional, Bonnin, Marthe, additional, Daudin, Magda, additional, Dubois, Catherine, additional, Francillon, Alain, additional, Frauger, Elisabeth, additional, Girault, Danièle, additional, Gourlay, Marie-Laurence, additional, Jolliet, Pascale, additional, Jaïs, Carmen Kreft, additional, Grimaldi, Lamiae, additional, Lièvre, Michel, additional, Maillère, Patricia, additional, Maugendre, Philippe, additional, Micallef, Joelle, additional, Miranda, Sara, additional, Pariente, Antoine, additional, Bigot, Sylvie Paulmier, additional, Pentel, Jonathan, additional, Prestat, Laure, additional, Pruvot, Fanny, additional, Ferrer, Valérie Querol, additional, Rocher, Fanny, additional, Saussier, Christel, additional, and Zanetti, Laura, additional

Published
2011
Full Text
View/download PDF

165. Place des études post-AMM dans le suivi des risques du médicament : cahier des charges et méthodologies

Author

Tubach, Florence, primary, Lamarque-Garnier, Véronique, additional, Castot, Anne, additional, Auclert, Laurent, additional, Bonnin, Marthe, additional, Daudin, Magda, additional, Dubois, Catherine, additional, Francillon, Alain, additional, Frauger, Elisabeth, additional, Girault, Danièle, additional, Gourlay, Marie-Laurence, additional, Jolliet, Pascale, additional, Jaïs, Carmen Kreft, additional, Grimaldi, Lamiae, additional, Lièvre, Michel, additional, Maillère, Patricia, additional, Maugendre, Philippe, additional, Micallef, Joelle, additional, Miranda, Sara, additional, Pariente, Antoine, additional, Bigot, Sylvie Paulmier, additional, Pentel, Jonathan, additional, Prestat, Laure, additional, Pruvot, Fanny, additional, Ferrer, Valérie Querol, additional, Rocher, Fanny, additional, Saussier, Christel, additional, and Zanetti, Laura, additional

Published
2011
Full Text
View/download PDF

166. Virological response to darunavir in patients infected with HIV is linked to darunavir resistance-associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological/pharmacolog

Author

Dailly, Eric, primary, Rodallec, Audrey, additional, Allavena, Clotilde, additional, Deslandes, Guillaume, additional, Garnier, Elisabeth, additional, Billaud, Eric, additional, Ferré, Virginie, additional, Reliquet, Véronique, additional, Bouquié, Régis, additional, Raffi, François, additional, and Jolliet, Pascale, additional

Published
2011
Full Text
View/download PDF

169. How to Best Define Target Populations of Medicines in View of Their Coverage by the National Health Insurance Scheme?

Author

Hamers, Françoise F., primary, Massol, Jacques, additional, Maillère, Patricia, additional, Alperovitch, Annick, additional, Auquier, Pascal, additional, Bamberger, Marion, additional, Banzet, Marie-Noëlle, additional, Boissel, Jean-Pierre, additional, Borel, Thomas, additional, Denis, Catherine, additional, Flahault, Antoine, additional, Gourlay, Marie-Laurence, additional, Jolliet, Pascale, additional, Joubert, Jean-Michel, additional, Lièvre, Michel, additional, Maison, Patrick, additional, Meyer, Arlette, additional, Moore, Nicholas, additional, Prestat-Sledziewski, Laure, additional, Rouby, Frank, additional, Schmidely, Nathalie, additional, Solesse, Anne, additional, Teisseire, Bernard, additional, Vasmant, Daniel, additional, Veron, Didier, additional, Villani, Patrick, additional, Zanetti, Laura, additional, Zureik, Mahmoud, additional, and Zylberman, Myriam, additional

Published
2010
Full Text
View/download PDF

170. Définition des populations cibles des médicaments : comment anticiper au mieux la définition des populations cibles en vue du remboursement ?

Author

Homers, Françoise F., primary, Massol, Jacques, additional, Maillère, Patricia, additional, Alperovitch, Annick, additional, Auquier, Pascal, additional, Bamberger, Marion, additional, Banzet, Marie-Noëlle, additional, Boissel, Jean-Pierre, additional, Borel, Thomas, additional, Denis, Catherine, additional, Flahault, Antoine, additional, Gourlay, Marie-Laurence, additional, Jolliet, Pascale, additional, Joubert, Jean-Michel, additional, Lièvre, Michel, additional, Maison, Patrick, additional, Meyer, Arlette, additional, Moore, Nicholas, additional, Prestat-Sledziewski, Laure, additional, Rouby, Frank, additional, Schmidely, Nathalie, additional, Solesse, Anne, additional, Teisseire, Bernard, additional, Vasmant, Daniel, additional, Veron, Didier, additional, Villani, Patrick, additional, Zanetti, Laura, additional, Zureik, Mahmoud, additional, and Zylberman, Myriam, additional

Published
2010
Full Text
View/download PDF

172. Bénéfice médical réel estimé par comparaisons indirectes

Author

Falissard, Bruno, primary, Zylberman, Myriam, additional, Cucherat, Michel, additional, Izard, Valérie, additional, Meyer, François, additional, Barna, Alexandre, additional, De Bels, Frédéric, additional, de Sahb, Rima, additional, Delonca, Jean, additional, Jolliet, Pascale, additional, Joubert, Jean-Michel, additional, Launois, Robert, additional, Le Jeunne, Claire, additional, Lièvre, Michel, additional, Gaudin, Florence Mahlberg, additional, Moser, Aurélie, additional, Perles, Patricia, additional, Pigeon, Martine, additional, Coquais, Cécile Rey, additional, Weisslinger, Nadine, additional, and Xerri, Bertrand, additional

Published
2009
Full Text
View/download PDF

173. Real Medical Benefit Assessed by Indirect Comparison

Author

Falissard, Bruno, primary, Zylberman, Myriam, additional, Cucherat, Michel, additional, Izard, Valérie, additional, Meyer, François, additional, Barna, Alexandre, additional, De Bels, Frédéric, additional, de Sahb, Rima, additional, Delonca, Jean, additional, Jolliet, Pascale, additional, Joubert, Jean-Michel, additional, Launois, Robert, additional, Le Jeunne, Claire, additional, Lièvre, Michel, additional, Gaudin, Florence Mahlberg, additional, Moser, Aurélie, additional, Perles, Patricia, additional, Pigeon, Martine, additional, Coquais, Cécile Rey, additional, Weisslinger, Nadine, additional, and Xerri, Bertrand, additional

Published
2009
Full Text
View/download PDF

175. Le bon usage du médicament : définition, référentiels, périmètre et champ d’application

Author

Bergmann, Jean-François, primary, Andrejak, Michel, additional, Bader, Jean-Pierre, additional, Bamberger, Marion, additional, Bilbault, Pascal, additional, Bordet, Régis, additional, Brouard, Agnès, additional, Burstin, Anne, additional, Castaigne, Alain, additional, Castot, Anne, additional, Coulomb, Alain, additional, Dahan, Muriel, additional, DeBels, Frédéric, additional, Duguay, Corinne, additional, Dumarcet, Nathalie, additional, Fender, Pierre, additional, Brentano, Christian Funck, additional, Giri, Isa-belle, additional, Jolliet, Pascale, additional, Pautrot, Murielle Jousselon, additional, Leclerc, Florence, additional, Gonidec, Patricia Le, additional, Maillere, Patricia, additional, Meyer, François, additional, Defarges, Thierry Moreau, additional, Obrecht, Olivier, additional, Paintaud, Gilles, additional, Petitcollot, Nicole, additional, Samama, Marc, additional, Sauterey, Julia, additional, Schiavi, Pierre, additional, Tcheng, Philippe, additional, Villani, Patrick, additional, Weber, Monique, additional, Darmon, Nadine Weisslinger, additional, and Zylberman, Myriam, additional

Published
2008
Full Text
View/download PDF

176. Good Medical Practice for Drugs. Definition, Guidelines, References, Field of Action and Applications

Author

Bergmann, Jean-François, primary, Andrejak, Michel, additional, Bader, Jean-Pierre, additional, Bamberger, Marion, additional, Bilbault, Pascal, additional, Bordet, Régis, additional, Brouard, Agnès, additional, Burstin, Anne, additional, Castaigne, Alain, additional, Castot, Anne, additional, Coulomb, Alain, additional, Dahan, Muriel, additional, DeBels, Frédéric, additional, Duguay, Corinne, additional, Dumarcet, Nathalie, additional, Fender, Pierre, additional, Brentano, Christian Funck, additional, Giri, Isa-belle, additional, Jolliet, Pascale, additional, Pautrot, Murielle Jousselon, additional, Leclerc, Florence, additional, Gonidec, Patricia Le, additional, Maillere, Patricia, additional, Meyer, François, additional, Defarges, Thierry Moreau, additional, Obrecht, Olivier, additional, Paintaud, Gilles, additional, Petitcollot, Nicole, additional, Samama, Marc, additional, Sauterey, Julia, additional, Schiavi, Pierre, additional, Tcheng, Philippe, additional, Villani, Patrick, additional, Weber, Monique, additional, Darmon, Nadine Weisslinger, additional, and Zylberman, Myriam, additional

Published
2008
Full Text
View/download PDF

177. Intégrité des données scientifiques : transparence des données recueillies au cours des essais cliniques, accès aux données

Author

Moore, Nicholas, primary, Juillet, Yves, additional, Bertoye, Pierre-Henri, additional, Baduel, Christophe, additional, Bernaud, Corinne, additional, Chêne, Geneviève, additional, Doucet, Dominique, additional, Dupin-Spriet, Thérèse, additional, Foltzer, Valérie, additional, Goehrs, Jean-Marie, additional, Golinelli, Danielle, additional, Hansel, Sylvie, additional, Husson, Jean-Marc, additional, Jolliet, Pascale, additional, LeCoent, Rémi, additional, Moret-Bailly, Joël, additional, Pelen, François, additional, Plétan, Yannick, additional, Rey-Quino, Catherine, additional, Reynier, Jean-Charles, additional, Simon, Tabassome, additional, Vlasto, Anne-Priscille, additional, Widler, Beat, additional, and Zannad, Faiez, additional

Published
2007
Full Text
View/download PDF

178. Integrity of Scientific Data: Transparency of Clinical Trial Data

Author

Moore, Nicholas, primary, Juillet, Yves, additional, Bertoye, Pierre-Henri, additional, Baduel, Christophe, additional, Bernaud, Corinne, additional, Chêne, Geneviève, additional, Doucet, Dominique, additional, Dupin-Spriet, Thérèse, additional, Foltzer, Valérie, additional, Goehrs, Jean-Marie, additional, Golinelli, Danielle, additional, Hansel, Sylvie, additional, Husson, Jean-Marc, additional, Jolliet, Pascale, additional, LeCoent, Rémi, additional, Moret-Bailly, Joël, additional, Pelen, François, additional, Plétan, Yannick, additional, Rey-Quino, Catherine, additional, Reynier, Jean-Charles, additional, Simon, Tabassome, additional, Vlasto, Anne-Priscille, additional, Widler, Beat, additional, and Zannad, Faiez, additional

Published
2007
Full Text
View/download PDF

179. Dependence on Prescription Benzodiazepines and Z-drugs Among Young to Middle-aged Patients in France.

Author

Guerlais, Marylène, Grall-Bronnec, Marie, Feuillet, Fanny, Gérardin, Marie, Jolliet, Pascale, and Victorri-Vigneau, Caroline

Subjects
DRUG addiction risk factors, MENTAL illness drug therapy, BENZODIAZEPINES, CHI-squared test, CONFIDENCE intervals, DRUG addiction, FACTOR analysis, FISHER exact test, INTERVIEWING, RESEARCH methodology, MEDICAL prescriptions, QUESTIONNAIRES, SEDATIVES, TRANQUILIZING drugs, MULTIPLE regression analysis, CROSS-sectional method, DATA analysis software, DESCRIPTIVE statistics, ODDS ratio
Abstract

Background: Benzodiazepines (BZD) and nonbenzodiazepines hypnotics (z-drugs) are recognized as one of the most widely prescribed medications in the world. Objectives: The purpose of the study was to assess the BZD and z-drugs dependence in young to middle-aged outpatients who were taking BZD/z-drugs on a chronic basis, and to characterize their profile. Methods: This is a forward-looking cross-sectional epidemiological study. Data were collected through a semi-structured interview within a network of partner pharmacies from the Nantes area, in France. All data were obtained exclusively through patients' declarations. 212 patients (19-64 years old) were included: they were considered dependent when they answered positively to at least three items of the DSM IV. A multivariate logistic regression and a principal component analysis (PCA) were carried out to determine their profile. Results: Almost half of the patients met criteria for BZD/z-drugs dependence. The risk to develop BZD/z-drugs dependence is significantly associated with psychiatric history and with the quantity of BZD/z-drugs that is taken. A two factor concept of dependence could be identified according to the PCA: one axis with items of 'tolerance' and 'long term administration or higher doses', and a second axis with 'concerned by treatment' and 'somatic consequences'. Conclusions/Importance: Among this BZD/z-drug dependent population, the two axes identified in the PCA represent two profiles of dependence: being in positive conditioning or suffering from negative consequences. Clinicians need to know them: these two clinical profiles may have an influence in terms of decision-making, especially to manage discontinuation. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

187. Pharmacists’ different profiles characterization about opioid substitution treatments

Author

Etcheverrigaray, François, Bétaud, Céline, Feuillet, Fanny, Grall-Bronnec, Marie, Jolliet, Pascale, and Victorri-Vigneau, Caroline

Abstract

Delivering practices of opioid substitution treatment (OST) in community pharmacies are heterogeneous. This study aims at drawing up an inventory and at characterizing different populations of pharmacists, regarding their practices and perceptions.

Published
2016
Full Text
View/download PDF

193. Protoxyde d’azote : oui il existe des troubles de l’usage !

Author

Guerlais, Marylène, Aquizerate, Aurelie, Gérardin, Marie, Istvan, Marion, Laforgue, Edouard-Jules, Daveluy, Amélie, Jolliet, Pascale, and Victorri-Vigneau, Caroline

Abstract

Depuis quelques années, la perception du détournement d’usage du protoxyde d’azote a évolué : en caricaturant, au départ il s’agissait de « proto-banalisé », sans conséquences rapportées, puis le « proto-neuro », avec les premières complications graves neurologiques signalées et aujourd’hui on voit apparaître le « proto-TUS », avec les troubles de l’usage et/ou critères apparentés rapportés. Ce travail décrit cette complication.

Published
2022
Full Text
View/download PDF

194. Accidental poisoning with brimonidine eye drops in a 9-day-old infant

Author

Deslandes, Guillaume, Bouquié, Regis, Boels, David, Gregoire, Matthieu, Grison-Hernando, Hélène, Azoulay, Claudine, Pineau, Alain, Monteil-Ganière, Catherine, Renaud, Christian, Dailly, Eric, Harry, Patrick, and Jolliet, Pascale

Abstract

Brimonidine is a selective alpha-2-adrenergic agonist used to treat glaucoma. We report a case of a 9-day-old female who developed, 90minutes after accidental ingestion of 3 eye drops of 0.2% brimonidine, coma, apnea, hyperglycemia and miosis requiring intubation and mechanical ventilation. Plasma concentration, 3hours after intake, was 11.7ng/mL. Normal consciousness was reached after 27hours. Apnea recovered slowly, normal breath was reached 47hours after accidental intake. This report adds to the existing evidence that brimonidine has serious systemic effects in newborns and can require fast and supportive management in intensive care unit.

Published
2015
Full Text
View/download PDF

195. L’acidose lactique précoce lors de l’intoxication massive au paracétamol : un trouble métabolique parfois méconnu

Author

Grégoire, Matthieu, Bretonniere, Cédric, Deslandes, Guillaume, Monteil-Ganiere, Catherine, Bouquié, Régis, Dailly, Eric, Renaud, Christian, Azoulay, Claudine, Pineau, Alain, Grison-Hernando, Hélène, and Jolliet, Pascale

Abstract

L’intoxication massive au paracétamol peut se compliquer d’une acidose lactique précoce sans anomalie du bilan hépatique. Nous présentons le cas d’un homme de 60ans, hospitalisé pour une intoxication médicamenteuse volontaire massive de 64g (soit 914mg/kg). Pendant les 3jours d’hospitalisation, ont été suivis en parallèle : la concentration plasmatique en paracétamol, en lactates, en ASAT et ALAT ainsi que le taux de prothrombine. Le bilan d’entrée aux urgences médicales révèle une paracétamolémie à 720mg/L (4766μmol/L), une acidose lactique décompensée (lactates : 10,2mmol/L ; pH : 7,27 ; trou anionique : 24mmol/L) et un bilan hépatique normal. Le traitement par N-acétyl-cystéine en perfusion intraveineuse est débuté avec une dose de charge de 150mg/kg en 1heure suivie de 50mg/kg en 4heures puis 100mg/kg en 16heures. Il est ensuite transféré en réanimation médicale dans un coma agité. L’acidose lactique se corrige en 12heures avec une cinétique des lactates superposable à celle du paracétamol. Du fait d’une paracétamolémie encore élevée 20heures après l’ingestion (1218μmol/L), le traitement par N-acétyl-cystéine est continué sur une base de 100mg/kg/24h. La paracétamolémie est infra-thérapeutique (inférieure à 33μmol/L) 44heures après l’ingestion. L’absence d’état de choc concomitant, d’état d’hypoxie ou de convulsions, de prise médicamenteuse autre, d’arguments en faveur d’une intoxication au monoxyde de carbone ainsi que d’une fonction hépatocellulaire normale permettent d’étayer l’hypothèse physiopathologique de l’intoxication massive au paracétamol. Ce type de cas, bien que très rare, doit être connu des cliniciens réanimateurs.

Published
2015
Full Text
View/download PDF

196. Medical, social, and law characteristics of intoxicant's users medically examined in police custody.

Author

Clement, Renaud, Gerardin, Marie, Vigneau Victorri, Caroline, Guigand, Gabriel, Wainstein, Laura, and Jolliet, Pascale

Abstract

Abstract: Introduction: There are no studies on medically examined persons in custody which specifically focus on identifying dependence profiles among users of intoxicants. Nonetheless, the characterisation of dependence profiles for intoxicants such as alcohol, cannabis, cocaine, heroin, amphetamines and their by-products is a medical necessity in this setting. Materials and methods: A prospective, monocentric, open-ended study conducted by structured questionnaire was carried out on detainees who admitted to having taken an intoxicant/s (tobacco, alcohol, drugs or illegal substances). Social, legal and medical data were collected. The aim of the study was to explore characteristics of these persons in police custody. Results: 817 questionnaires were examined. More than one-third have a dependence on at least one substance. 37.7% were dependant of tobacco, 86.5% of drinkers, 24.7% of cannabis users. Of these, 90.1% were from men with a mean age of 29.4 years, 40% from individuals living alone, 25.7% from persons with no financial means and 19.6% from homeless persons. 10% were believed to be suffering from mental illness, 7.2% were thought to be asthmatic, 3% to have a chronic infection, and 2.9% to have epilepsy. 36.2% reportedly received treatment, 37.5% of which included benzodiazepine and 20.3% opiate substitution therapy. Incidence of psychological and psychiatric disorders is close to 10% of intoxicant detainees. Discussion: In this study, some of the stated pathologies occur in ratios similar to those in other published results. But, there is a high, and probably underestimated, prevalence of psychological and psychiatric disorders in this population of detainees reporting exposure to intoxicant or illegal substances. [Copyright &y& Elsevier]

Published
2013
Full Text
View/download PDF

198. Virological response to darunavir in patients infected with HIV is linked to darunavir resistance-associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological/pharmacological parameters

Author

Dailly, Eric, Rodallec, Audrey, Allavena, Clotilde, Deslandes, Guillaume, Garnier, Elisabeth, Billaud, Eric, Ferré, Virginie, Reliquet, Véronique, Bouquié, Régis, Raffi, François, and Jolliet, Pascale

Subjects
RETROSPECTIVE studies, HIV-positive persons, DARUNAVIR, DRUG resistance, GENETIC mutation
Abstract

The relationships between virological (darunavir resistance-associated mutations), pharmacological (darunavir trough plasma concentration), combined virological/pharmacological [darunavir genotypic inhibitory quotient (GIQ)] parameters and virological response were evaluated in experienced patients infected with human immunodeficiency virus. In this retrospective study (48 patients), the relationship between these parameters and the virological response was investigated by multivariate logistic regression. Darunavir GIQ is defined as the ratio between darunavir trough plasma concentration and the count of darunavir resistance-associated mutations (V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V, L89V) corrected or not corrected by the count of mutations with positive impact (V82A and E35D). The pharmacological and combined virological/pharmacological parameters failed to predict virological response. The count of darunavir resistance-associated mutations corrected by the count of V82A and E35D mutations was the single parameter significantly ( P = 0.027) associated with virological response. This result suggests that both negative and positive impacts of mutations including V82A and E35D should be considered to predict virological response in experienced patients. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

199. First Case of Symmetric Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) due to Rivastigmine?

Author

Allain-Veyrac, Gwenaëlle, Lebreton, Anne, Collonnier, Catherine, and Jolliet, Pascale

Subjects
CHOLINESTERASE inhibitors, DEMENTIA, DRUG eruptions, EXANTHEMA, SYMPTOMS, DIAGNOSIS
Abstract

The term 'baboon syndrome' was introduced in 1984 to describe a special form of systemic, contact-type dermatitis that occurs after ingestion or systemic absorption of a contact allergen in individuals previously sensitized by topical exposure to the same allergen in the same areas. Its clinical picture presents as an erythema of the buttocks and upper inner thighs resembling the red bottom of baboons. This reaction was originally observed with mercury, nickel, and ampicillin. In 2004, some authors proposed the acronym SDRIFE standing for 'symmetric drug-related intertriginous and flexural exanthema' specifically for cases elicited by systemically administered drugs. Since 1984, about 100 cases have been reported in the literature; for most of the concerned drugs, previous skin sensitization or possible cross-sensitization has not been shown. We report the first case of SDRIFE due to rivastigmine, with the exception of an erythematous maculopapular eruption due to rivastigmine that was previously reported. Rivastigmine is a reversible and noncompetitive acetyicholinesterase inhibitor used for the treatment of Alzheimer disease. SDRIFE is an important condition to keep in mind in order to avoid a misdiagnosis when dealing with other exanthematous disorders and to prevent re-exposure to the responsible allergen in the future. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

200. Management of cannabis use during pregnancy: an assessment of healthcare professionals' practices.

Author

Gérardin, Marie, Victorri-Vigneau, Caroline, Louvigné, Cécile, Rivoal, Marion, and Jolliet, Pascale

Subjects
MEDICAL personnel, PREGNANT women, CANNABIS (Genus), GYNECOLOGISTS, OBSTETRICIANS
Abstract

The article presents a study on the practices of health care professionals regarding the detection and care of pregnant women who are using cannabis. A group of gynaecologists, obstetricians and midwives in Loire-Atlantic district in France were asked to answer a questionnaire which deals with the detection methods of using cannabis in pregnant women. The study found that not all healthcare professionals are informed about the risk of consuming cannabis during pregnancy which, according to the authors, call for healthcare training for all practitioners.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results